registry_id stringlengths 17 17 | year int64 2.02k 2.02k | age int64 0 94 | age_group stringclasses 8
values | sex stringclasses 2
values | cancer_type stringclasses 15
values | morphology stringclasses 7
values | grade stringclasses 5
values | basis_of_diagnosis stringclasses 4
values | vital_status stringclasses 3
values | survival_months float64 0 369 | scenario stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|
RW-KGL-2019-00001 | 2,019 | 6 | 0-14 | Male | Other | Squamous cell carcinoma | Grade IV | Microscopy | Alive | 37.8 | moderate_burden |
RW-KGL-2021-00002 | 2,021 | 40 | 35-44 | Male | Colorectum | Squamous cell carcinoma | Grade II | DCO | Dead | 14.9 | moderate_burden |
RW-KGL-2021-00003 | 2,021 | 75 | 75+ | Female | Other | Squamous cell carcinoma | Grade IV | Microscopy | Alive | 56 | moderate_burden |
RW-KGL-2015-00004 | 2,015 | 45 | 45-54 | Female | Cervix uteri | Adenocarcinoma | Grade III | Microscopy | Alive | 13.2 | moderate_burden |
RW-KGL-2019-00005 | 2,019 | 57 | 55-64 | Male | Kaposi sarcoma | Lymphoma | Grade II | Microscopy | Alive | 47.2 | moderate_burden |
RW-KGL-2016-00006 | 2,016 | 69 | 65-74 | Male | Colorectum | Sarcoma | Grade IV | Imaging + clinical | Dead | 27 | moderate_burden |
RW-KGL-2015-00007 | 2,015 | 52 | 45-54 | Female | Breast | Lymphoma | Grade III | Microscopy | Alive | 45.4 | moderate_burden |
RW-KGL-2019-00008 | 2,019 | 72 | 65-74 | Female | Ovary | Sarcoma | Grade II | Microscopy | Alive | 13.1 | moderate_burden |
RW-KGL-2020-00009 | 2,020 | 53 | 45-54 | Female | Ovary | Squamous cell carcinoma | Unknown | Microscopy | Dead | 26.8 | moderate_burden |
RW-KGL-2021-00010 | 2,021 | 41 | 35-44 | Female | Thyroid | Non-keratinizing | Grade II | Clinical only | Lost | 37 | moderate_burden |
RW-KGL-2016-00011 | 2,016 | 73 | 65-74 | Male | Other | Adenocarcinoma | Grade II | Microscopy | Dead | 62 | moderate_burden |
RW-KGL-2021-00012 | 2,021 | 49 | 45-54 | Female | Other | Sarcoma | Grade III | Imaging + clinical | Dead | 5.8 | moderate_burden |
RW-KGL-2021-00013 | 2,021 | 50 | 45-54 | Female | Other | Sarcoma | Grade II | Microscopy | Alive | 0.6 | moderate_burden |
RW-KGL-2020-00014 | 2,020 | 33 | 25-34 | Male | Colorectum | Sarcoma | Grade I | Microscopy | Lost | 29.3 | moderate_burden |
RW-KGL-2016-00015 | 2,016 | 27 | 25-34 | Female | Breast | Squamous cell carcinoma | Grade I | Imaging + clinical | Alive | 15.3 | moderate_burden |
RW-KGL-2020-00016 | 2,020 | 72 | 65-74 | Female | Other | Other | Grade II | Microscopy | Dead | 93.6 | moderate_burden |
RW-KGL-2016-00017 | 2,016 | 46 | 45-54 | Male | Non-Hodgkin lymphoma | Other | Grade II | Microscopy | Alive | 32.7 | moderate_burden |
RW-KGL-2020-00018 | 2,020 | 45 | 45-54 | Female | Other | Adenocarcinoma | Grade I | Microscopy | Alive | 10.4 | moderate_burden |
RW-KGL-2017-00019 | 2,017 | 58 | 55-64 | Male | Other | Lymphoma | Unknown | Microscopy | Alive | 76.6 | moderate_burden |
RW-KGL-2019-00020 | 2,019 | 60 | 55-64 | Female | Cervix uteri | Lymphoma | Grade III | Microscopy | Dead | 21.8 | moderate_burden |
RW-KGL-2018-00021 | 2,018 | 57 | 55-64 | Male | Other | Squamous cell carcinoma | Grade III | Microscopy | Alive | 15.1 | moderate_burden |
RW-KGL-2020-00022 | 2,020 | 58 | 55-64 | Female | Cervix uteri | Squamous cell carcinoma | Grade IV | Microscopy | Dead | 20.4 | moderate_burden |
RW-KGL-2021-00023 | 2,021 | 48 | 45-54 | Male | Prostate | Squamous cell carcinoma | Grade III | Microscopy | Alive | 32.6 | moderate_burden |
RW-KGL-2020-00024 | 2,020 | 67 | 65-74 | Female | Cervix uteri | Squamous cell carcinoma | Grade II | Microscopy | Alive | 20.8 | moderate_burden |
RW-KGL-2018-00025 | 2,018 | 40 | 35-44 | Female | Other | Squamous cell carcinoma | Grade III | Microscopy | Dead | 2.5 | moderate_burden |
RW-KGL-2016-00026 | 2,016 | 58 | 55-64 | Female | Cervix uteri | Squamous cell carcinoma | Grade II | Microscopy | Lost | 19 | moderate_burden |
RW-KGL-2021-00027 | 2,021 | 63 | 55-64 | Male | Kaposi sarcoma | Adenocarcinoma | Grade II | Microscopy | Dead | 21.6 | moderate_burden |
RW-KGL-2017-00028 | 2,017 | 38 | 35-44 | Male | Prostate | Non-keratinizing | Unknown | Microscopy | Alive | 4.5 | moderate_burden |
RW-KGL-2018-00029 | 2,018 | 37 | 35-44 | Female | Breast | Leukemia | Grade I | Microscopy | Lost | 22 | moderate_burden |
RW-KGL-2020-00030 | 2,020 | 53 | 45-54 | Female | Ovary | Non-keratinizing | Grade III | Microscopy | Lost | 4.4 | moderate_burden |
RW-KGL-2019-00031 | 2,019 | 46 | 45-54 | Female | Other | Leukemia | Grade III | Microscopy | Dead | 4.6 | moderate_burden |
RW-KGL-2019-00032 | 2,019 | 65 | 65-74 | Female | Breast | Sarcoma | Grade III | Microscopy | Alive | 25.8 | moderate_burden |
RW-KGL-2016-00033 | 2,016 | 50 | 45-54 | Male | Stomach | Sarcoma | Grade II | Microscopy | Alive | 88.1 | moderate_burden |
RW-KGL-2016-00034 | 2,016 | 23 | 15-24 | Female | Breast | Non-keratinizing | Grade II | Microscopy | Dead | 1.3 | moderate_burden |
RW-KGL-2020-00035 | 2,020 | 31 | 25-34 | Female | Cervix uteri | Squamous cell carcinoma | Grade II | Clinical only | Dead | 35.5 | moderate_burden |
RW-KGL-2020-00036 | 2,020 | 72 | 65-74 | Female | Breast | Sarcoma | Grade II | Microscopy | Alive | 16.3 | moderate_burden |
RW-KGL-2016-00037 | 2,016 | 35 | 35-44 | Male | Kaposi sarcoma | Adenocarcinoma | Grade IV | Imaging + clinical | Dead | 135.9 | moderate_burden |
RW-KGL-2015-00038 | 2,015 | 38 | 35-44 | Female | Other | Adenocarcinoma | Grade II | Clinical only | Alive | 0.4 | moderate_burden |
RW-KGL-2021-00039 | 2,021 | 46 | 45-54 | Female | Other | Lymphoma | Grade II | Microscopy | Alive | 33.7 | moderate_burden |
RW-KGL-2017-00040 | 2,017 | 63 | 55-64 | Male | Other | Lymphoma | Grade I | Microscopy | Alive | 7.7 | moderate_burden |
RW-KGL-2015-00041 | 2,015 | 36 | 35-44 | Female | Cervix uteri | Adenocarcinoma | Grade II | Microscopy | Alive | 11 | moderate_burden |
RW-KGL-2018-00042 | 2,018 | 60 | 55-64 | Female | Other | Squamous cell carcinoma | Grade I | Microscopy | Dead | 11.4 | moderate_burden |
RW-KGL-2018-00043 | 2,018 | 52 | 45-54 | Female | Other | Adenocarcinoma | Grade I | Microscopy | Alive | 18.8 | moderate_burden |
RW-KGL-2021-00044 | 2,021 | 40 | 35-44 | Female | Cervix uteri | Non-keratinizing | Grade I | Microscopy | Alive | 52.2 | moderate_burden |
RW-KGL-2017-00045 | 2,017 | 32 | 25-34 | Female | Cervix uteri | Sarcoma | Grade II | Imaging + clinical | Dead | 1.1 | moderate_burden |
RW-KGL-2017-00046 | 2,017 | 51 | 45-54 | Male | Other | Squamous cell carcinoma | Grade II | Microscopy | Alive | 33.8 | moderate_burden |
RW-KGL-2021-00047 | 2,021 | 36 | 35-44 | Female | Breast | Non-keratinizing | Grade I | Microscopy | Alive | 31.4 | moderate_burden |
RW-KGL-2015-00048 | 2,015 | 47 | 45-54 | Female | Other | Adenocarcinoma | Grade III | Microscopy | Dead | 45.8 | moderate_burden |
RW-KGL-2019-00049 | 2,019 | 73 | 65-74 | Female | Other | Squamous cell carcinoma | Grade II | Microscopy | Alive | 10.5 | moderate_burden |
RW-KGL-2019-00050 | 2,019 | 61 | 55-64 | Female | Breast | Squamous cell carcinoma | Unknown | Imaging + clinical | Alive | 59.5 | moderate_burden |
RW-KGL-2017-00051 | 2,017 | 59 | 55-64 | Female | Breast | Squamous cell carcinoma | Grade III | Microscopy | Alive | 9.5 | moderate_burden |
RW-KGL-2019-00052 | 2,019 | 37 | 35-44 | Female | Other | Lymphoma | Grade III | Imaging + clinical | Dead | 26.7 | moderate_burden |
RW-KGL-2019-00053 | 2,019 | 26 | 25-34 | Male | Hodgkin lymphoma | Lymphoma | Grade III | Clinical only | Dead | 4 | moderate_burden |
RW-KGL-2019-00054 | 2,019 | 47 | 45-54 | Male | Liver | Sarcoma | Grade II | Microscopy | Dead | 8.9 | moderate_burden |
RW-KGL-2020-00055 | 2,020 | 36 | 35-44 | Male | Prostate | Sarcoma | Unknown | Imaging + clinical | Dead | 21.5 | moderate_burden |
RW-KGL-2021-00056 | 2,021 | 63 | 55-64 | Female | Breast | Squamous cell carcinoma | Grade III | DCO | Dead | 25 | moderate_burden |
RW-KGL-2019-00057 | 2,019 | 41 | 35-44 | Female | Breast | Adenocarcinoma | Grade I | Imaging + clinical | Dead | 105.6 | moderate_burden |
RW-KGL-2017-00058 | 2,017 | 60 | 55-64 | Female | Cervix uteri | Adenocarcinoma | Grade III | Imaging + clinical | Alive | 6.4 | moderate_burden |
RW-KGL-2017-00059 | 2,017 | 51 | 45-54 | Male | Kaposi sarcoma | Non-keratinizing | Grade II | Clinical only | Alive | 49.2 | moderate_burden |
RW-KGL-2020-00060 | 2,020 | 58 | 55-64 | Female | Other | Squamous cell carcinoma | Unknown | Clinical only | Alive | 6.4 | moderate_burden |
RW-KGL-2019-00061 | 2,019 | 48 | 45-54 | Male | Colorectum | Adenocarcinoma | Grade IV | Clinical only | Lost | 2.5 | moderate_burden |
RW-KGL-2019-00062 | 2,019 | 25 | 25-34 | Female | Breast | Sarcoma | Grade III | Microscopy | Dead | 9.6 | moderate_burden |
RW-KGL-2020-00063 | 2,020 | 67 | 65-74 | Male | Prostate | Sarcoma | Grade I | Microscopy | Dead | 4.1 | moderate_burden |
RW-KGL-2021-00064 | 2,021 | 61 | 55-64 | Male | Kaposi sarcoma | Adenocarcinoma | Grade IV | Microscopy | Dead | 7.1 | moderate_burden |
RW-KGL-2015-00065 | 2,015 | 68 | 65-74 | Female | Breast | Adenocarcinoma | Grade II | Imaging + clinical | Alive | 15.6 | moderate_burden |
RW-KGL-2017-00066 | 2,017 | 57 | 55-64 | Female | Cervix uteri | Sarcoma | Grade II | Microscopy | Alive | 5.1 | moderate_burden |
RW-KGL-2019-00067 | 2,019 | 57 | 55-64 | Female | Cervix uteri | Squamous cell carcinoma | Grade I | Imaging + clinical | Dead | 54 | moderate_burden |
RW-KGL-2017-00068 | 2,017 | 31 | 25-34 | Female | Breast | Squamous cell carcinoma | Grade III | DCO | Alive | 43.2 | moderate_burden |
RW-KGL-2021-00069 | 2,021 | 63 | 55-64 | Female | Thyroid | Non-keratinizing | Grade II | Microscopy | Alive | 25.1 | moderate_burden |
RW-KGL-2017-00070 | 2,017 | 55 | 55-64 | Female | Other | Other | Grade IV | DCO | Alive | 8.3 | moderate_burden |
RW-KGL-2018-00071 | 2,018 | 67 | 65-74 | Female | Cervix uteri | Non-keratinizing | Grade III | Microscopy | Alive | 13.4 | moderate_burden |
RW-KGL-2017-00072 | 2,017 | 39 | 35-44 | Female | Breast | Adenocarcinoma | Grade IV | Microscopy | Alive | 31.3 | moderate_burden |
RW-KGL-2020-00073 | 2,020 | 68 | 65-74 | Male | Colorectum | Leukemia | Grade IV | Microscopy | Dead | 8.3 | moderate_burden |
RW-KGL-2017-00074 | 2,017 | 56 | 55-64 | Female | Breast | Non-keratinizing | Grade III | Microscopy | Dead | 7.5 | moderate_burden |
RW-KGL-2016-00075 | 2,016 | 37 | 35-44 | Female | Breast | Sarcoma | Grade I | Microscopy | Dead | 55.7 | moderate_burden |
RW-KGL-2016-00076 | 2,016 | 27 | 25-34 | Female | Cervix uteri | Lymphoma | Grade II | Imaging + clinical | Dead | 13.9 | moderate_burden |
RW-KGL-2017-00077 | 2,017 | 62 | 55-64 | Male | Other | Adenocarcinoma | Unknown | Clinical only | Lost | 9 | moderate_burden |
RW-KGL-2018-00078 | 2,018 | 43 | 35-44 | Female | Other | Squamous cell carcinoma | Grade II | DCO | Alive | 24.3 | moderate_burden |
RW-KGL-2017-00079 | 2,017 | 56 | 55-64 | Male | Non-Hodgkin lymphoma | Sarcoma | Unknown | DCO | Dead | 79.6 | moderate_burden |
RW-KGL-2018-00080 | 2,018 | 16 | 15-24 | Male | Non-Hodgkin lymphoma | Squamous cell carcinoma | Grade I | DCO | Lost | 15.2 | moderate_burden |
RW-KGL-2020-00081 | 2,020 | 46 | 45-54 | Male | Hodgkin lymphoma | Sarcoma | Grade III | Microscopy | Dead | 2.3 | moderate_burden |
RW-KGL-2016-00082 | 2,016 | 42 | 35-44 | Female | Cervix uteri | Non-keratinizing | Grade I | Microscopy | Alive | 2.8 | moderate_burden |
RW-KGL-2018-00083 | 2,018 | 16 | 15-24 | Female | Cervix uteri | Lymphoma | Grade III | DCO | Alive | 11.7 | moderate_burden |
RW-KGL-2020-00084 | 2,020 | 50 | 45-54 | Female | Breast | Sarcoma | Grade I | Microscopy | Dead | 1.7 | moderate_burden |
RW-KGL-2019-00085 | 2,019 | 51 | 45-54 | Male | Stomach | Sarcoma | Grade II | Clinical only | Dead | 22.4 | moderate_burden |
RW-KGL-2021-00086 | 2,021 | 71 | 65-74 | Male | Other | Sarcoma | Unknown | Microscopy | Dead | 33.5 | moderate_burden |
RW-KGL-2020-00087 | 2,020 | 65 | 65-74 | Male | Liver | Squamous cell carcinoma | Grade II | Imaging + clinical | Alive | 1.8 | moderate_burden |
RW-KGL-2018-00088 | 2,018 | 29 | 25-34 | Female | Other | Non-keratinizing | Grade II | Clinical only | Alive | 16.2 | moderate_burden |
RW-KGL-2019-00089 | 2,019 | 55 | 55-64 | Female | Cervix uteri | Non-keratinizing | Grade IV | Clinical only | Alive | 0.4 | moderate_burden |
RW-KGL-2016-00090 | 2,016 | 52 | 45-54 | Female | Cervix uteri | Adenocarcinoma | Grade IV | Imaging + clinical | Dead | 53.8 | moderate_burden |
RW-KGL-2015-00091 | 2,015 | 71 | 65-74 | Female | Other | Adenocarcinoma | Grade III | Microscopy | Lost | 2.9 | moderate_burden |
RW-KGL-2019-00092 | 2,019 | 82 | 75+ | Female | Cervix uteri | Squamous cell carcinoma | Grade II | Microscopy | Alive | 18.6 | moderate_burden |
RW-KGL-2017-00093 | 2,017 | 20 | 15-24 | Female | Breast | Lymphoma | Unknown | Microscopy | Alive | 19.6 | moderate_burden |
RW-KGL-2015-00094 | 2,015 | 61 | 55-64 | Female | Breast | Non-keratinizing | Grade III | Imaging + clinical | Dead | 6 | moderate_burden |
RW-KGL-2017-00095 | 2,017 | 93 | 75+ | Female | Thyroid | Squamous cell carcinoma | Unknown | Microscopy | Alive | 97.5 | moderate_burden |
RW-KGL-2015-00096 | 2,015 | 52 | 45-54 | Female | Cervix uteri | Lymphoma | Grade IV | Clinical only | Alive | 25.1 | moderate_burden |
RW-KGL-2016-00097 | 2,016 | 15 | 15-24 | Male | Other | Adenocarcinoma | Unknown | Microscopy | Dead | 46.3 | moderate_burden |
RW-KGL-2016-00098 | 2,016 | 12 | 0-14 | Female | Breast | Squamous cell carcinoma | Unknown | Clinical only | Dead | 16.5 | moderate_burden |
RW-KGL-2018-00099 | 2,018 | 73 | 65-74 | Female | Cervix uteri | Sarcoma | Grade III | Microscopy | Alive | 4.9 | moderate_burden |
RW-KGL-2015-00100 | 2,015 | 31 | 25-34 | Female | Breast | Squamous cell carcinoma | Grade IV | Microscopy | Alive | 31.3 | moderate_burden |
⚠️ Synthetic dataset — Parameterized from published SSA literature, not real observations. Not suitable for empirical analysis or policy inference.
Rwanda Cancer Registry - Kigali
Abstract
This synthetic dataset represents population-based cancer registry data for kigali and is designed to address the significant data gap in cancer research for sub-Saharan Africa. The dataset contains 2,000-3,000 per scenario records per scenario with key epidemiological parameters grounded in GLOBOCAN 2022 estimates, WHO reports, and peer-reviewed literature from the African Cancer Registry Network (AFCRN).
The age-standardized incidence rate (ASIR) of Rwanda Cancer Registry in the target population is approximately 92.0 per 100,000 population (GLOBOCAN 2022). This dataset provides training data for cancer epidemiology modeling, health systems research, and machine learning applications in oncology.
1. Introduction
1.1 Problem Statement
Cancer incidence in sub-Saharan Africa is rising rapidly, with estimated new cases reaching over 1 million annually by 2030. However, the region faces a critical shortage of granular cancer data for research, policy development, and health system planning. Population-based cancer registries cover less than 5% of the African population, creating significant gaps in understanding the true burden of disease.
1.2 Data Gap
- Limited population-based registry data outside major cities
- Missing survival and outcome data from most facilities
- Underrepresentation of pediatric and rare cancers
- Lack of treatment access and outcome metrics
1.3 Purpose
This dataset supports:
- Cancer burden estimation and projection modeling
- Health system capacity planning
- Machine learning for risk prediction and triage
- Epidemiological research on cancer patterns
- Policy development for cancer control programs
2. Methodology
2.1 Target Population
- Geographic scope: Rwanda
- Population represented: Urban and rural populations
- Time period: Variable by data source (2010-2025)
2.2 Variable Selection
Variables were selected based on:
- IARC/WHO cancer registry standards
- Data availability in African cancer registries
- Clinical relevance for cancer control
2.3 Epidemiological Parameterization
All parameters are derived from:
- GLOBOCAN 2022 (IARC)
- WHO Cancer Reports
- African Cancer Registry Network (AFCRN)
- DHS/MICS survey data
- Peer-reviewed literature
2.4 Scenario Design
| Scenario | Description | Records |
|---|---|---|
| low_burden | Low cancer burden setting | Varies by dataset |
| moderate_burden | Standard burden setting | Varies by dataset |
| high_burden | High burden / late presentation | Varies by dataset |
2.5 Generation Process
Generation follows a conditional sampling approach based on directed acyclic graphs (DAGs) representing causal relationships between variables:
- Sample demographic variables (age, sex, location)
- Sample cancer type conditional on demographics
- Sample clinical variables (stage, morphology, grade)
- Sample treatment and outcome variables
- Derive survival times from outcome models
3. Dataset Description
3.1 Key Variables
Population-based cancer registry data for Kigali
3.2 Data Quality
- All categorical distributions validated against published literature
- Continuous variables modeled with appropriate statistical distributions
- Survival times based on exponential models with literature-derived parameters
4. Validation
4.1 Prevalence Verification
All prevalence values are validated against GLOBOCAN 2022 and published registry reports.
4.2 Distribution Quality
- Age and sex distributions match expected patterns
- Cancer type frequencies align with regional estimates
4.3 Clinical Plausibility
- No biologically impossible combinations
- Treatment patterns consistent with resource-limited settings
5. Usage
5.1 Loading with HuggingFace
from datasets import load_dataset
ds = load_dataset("electricsheepafrica/rwanda-cancer-kigali", "moderate_burden")
5.2 Loading from CSV
import pandas as pd
df = pd.read_csv("rwanda_cancer_kigali_moderate_burden.csv")
6. Limitations
- Synthetic data: Generated from aggregated statistics, not individual patient records
- Simplified correlations: May not capture complex dependencies
- Not for clinical use: Designed for research and ML training only
7. References
- GLOBOCAN 2022. IARC Cancer Observatory.
- African Cancer Registry Network (AFCRN).
- WHO Cancer Control Reports.
- DHS/MICS Survey Data.
Citation
@dataset{rwanda_cancer_kigali,
title={Rwanda Cancer Registry - Kigali},
author={Electric Sheep Africa},
year={2025},
publisher={HuggingFace},
dataset_url={https://huggingface.co/datasets/electricsheepafrica/rwanda-cancer-kigali}
}
License
CC-BY-4.0
- Downloads last month
- 18